This trial will demonstrate localised uptake of a radiolabelled fungal component (siderophore) in areas of known specific invasive fungal (Aspergillus) infection.
This open label, single centre, proof of concept pilot imaging trial will evaluate technique for the diagnosis of invasive Aspergillus infection. It aims to demonstrate uptake of the gallium-siderophore tracer at sites of known proven/probable invasive aspergillus app infection. It will also assess the safety and tolerability of this technique. 10 patients within 2 weeks of proven or probable invasive fungal infection (IFI) diagnosis will be recruited to this study over a period of 12-24 months.
Study Type
OBSERVATIONAL
Enrollment
10
68Ga-labelled TAFC PET/CT scan (whole body)
Peter MacCallum Cancer Centre
Melbourne, Victoria, Australia
RECRUITINGUptake of radiolabelled siderophore (68Ga-TAFC) in patients with proven/probable invasive Aspergillosis
The maximum standardized uptake value (SUVmax) is widely used for measuring the uptake of FDG by malignant tissue.
Time frame: At 60 minutes
Physiologic bio distribution
SUVmax in mediastinal blood pool, and any organs with uptake including liver, spleen and marrow
Time frame: Evaluated up to 3 hours following injection of radiotracer
Safety of 68Ga-TAFC-PET/CT
Adverse events defined by CTCAE v5
Time frame: Evaluated within 24 hours of scan
Findings compared to CT and/or 18F-FDG PET/CT
Descriptive comparison of the siderophore PET to standard of care imaging - looking at areas of uptake and if this corresponds to areas of presumed infection on SOC PET or CT
Time frame: At 60 minutes
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.